Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Sawai Announces Revised 3-year Management Plan
February 28, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 28, 2005
- MREAC to Begin Improving Education, Training System
February 28, 2005
- BULLETIN
February 28, 2005
- Fujisawa to Transfer Marketing of 11 Products to 3 Companies
February 28, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 28, 2005
- Daiichi Suntory Transfer Sales of Farom to Maruho
February 28, 2005
- Meet the Leaders (40)
February 28, 2005
- BUSINESS NEWS IN BRIEF
February 28, 2005
- Sunrise Plan Aims at Sales of \360 Billion in 2010: Mr Nagayama of Chugai
February 28, 2005
- Transitional Period for Labeling Changes in Rx-only Drug Announced
February 28, 2005
- Korosho Issues Guide on Preparing Manufacturing Applications
February 28, 2005
- Drug Production Statistics Data to Be Reported More Promptly
February 28, 2005
- 2005 Will Be a Major Turning Point: Prefectural Health Officials Meeting
February 28, 2005
- BUSINESS NEWS IN BRIEF
February 21, 2005
- MEDICAL DEVICE NEWS IN BRIEF
February 21, 2005
- Alliance with PPD Enables Us to Meet Various Needs of Clients: Ms Oishi of CMIC
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- 1st 3 Qtrs Business Results
February 21, 2005
- Nippon Kayaku to Increase Focus on Oncology
February 21, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…